Global Ranibizumab Market Size Expected to Reach $4208 Million by 2029, Growing at a CAGR of 2.07%, Cover Regional Analysis
In the future, with the increasing number of people suffering from ophthalmic diseases, the demand for ranibizumab in the market will increase, which will drive further market growth. It is expected that by 2029, the global market revenue of ranibizumab will increase to $4208 million. The estimated CAGR for 2024-2029 is 2.07%.
Ranibizumab is a monoclonal antibody fragment (FAB), as well as an antibody against vascular endothelial growth factor (VEGF) and an inhibitor of angiogenesis. It is obtained from the same parent mouse antibody as bevacizumab, but is much smaller than the parent molecule and can bind more tightly to vascular endothelial growth factor-A (VEGF-A).
Market size: According to our research data, the global revenue of the ranibizumab market is expected to reach $3799 million in 2024, an increase of 3.14% compared to 2023.
Market competition: Roche and Novartis are the core global suppliers of ranibizumab, holding approximately 98% of the market share.
Related Market Research Report: 2024 Global Ranibizumab Market Analysis Report, Key Competitors, Market Effect Factors, Growth, And Forecast
Leizumab is mainly used to treat eye neovascular diseases, including wAMD、DR、DEM、Mcnv、RVO. Among them, the treatment of wAMD is the largest downstream application market, with an estimated application share of 43.37% in 2024.
Market Segmentation by Company
Market Segmentation by Classification
Global Ranibizumab Market Revenue and Market Share by Application Forecast
Source: www.globalmarketmonitor.com
Analysis of Market Development in Major Regions
From a regional perspective, the global market for ranibizumab is concentrated in three major regions: North America, Europe, and Asia Pacific. Among them, North America is the largest sales market. Data shows that the sales of ranibizumab in North America are expected to reach 1335.2k vails in 2024, accounting for an estimated 45.35% of the global total consumption; The European and Asia Pacific markets are expected to rank second and third with a share of 28.50% and 17.44%, respectively.
Which regions Market are Analyzed in This Report?
North America (United States, Canada, and Mexico)
Europe (Germany, UK, Spain, France, Italy, Russia and Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, etc. )
South America (Brazil, Argentina, Columbia, etc.)
GCC(Bahrain, Kuwait, Oman, etc.)
Africa(Nigeria, South Africa, Egypt, etc.)
Oceania(Australia and New Zealand)
Access?Complete?Report?Description,?TOC,?Figures?&?Chart@https://www.globalmarketmonitor.com/reports/1721609-ranibizumab-market-report.html
TABLE OF CONTENTS
Chapter 1 Ranibizumab Market Overview
Chapter 2 Market Dynamics
领英推荐
Chapter 3 Market Industry Chain Analysis
Chapter 4 Global Market Overview
Chapter 5 Geography Analysis
Chapter 6 North America Geography Trend
Chapter 7 Europe Geography Trend
Chapter 8 Asia Geography Trend
Chapter 9 Africa Geography Trend
Chapter 10 Middle East Geography Trend
Chapter 11 Latin America and the Caribbean Geography Trend
Chapter 12 Oceania Geography Trend
Chapter 13 Classification and End-User Trend Analysis
Chapter 14 Geography Import & Export
Chapter 15 Ranibizumab - Company List
Chapter 16 Global Ranibizumab Market Competition
Chapter 17 Key Findings and Conclusion